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Abstract 
Despite considerable progress with our understanding of glioblastoma multiforme (GBM) and the precise 
delivery of radiotherapy, the prognosis for GBM patients is still unfavorable with tumor recurrence due 
to radioresistance being a major concern. We recently developed a cross-linked iron oxide nanoparticle 
conjugated to azademethylcolchicine (CLIO-ICT) to target and eradicate a subpopulation of quiescent 
cells, glioblastoma initiating cells (GICs), which could be a reason for radioresistance and tumor relapse. 
The purpose of our study was to investigate if CLIO-ICT has an additive therapeutic effect to enhance the 
response of GBMs to ionizing radiation. 
Methods: NSG mice bearing human GBMs and C57BL/6J mice bearing murine GBMs received 
CLIO-ICT, radiation, or combination treatment. The mice underwent pre- and post-treatment magnetic 
resonance imaging (MRI) scans, bioluminescence imaging (BLI), and histological analysis. Tumor 
nanoparticle enhancement, tumor flux, microvessel density, GIC, and apoptosis markers were compared 
between different groups using a one-way ANOVA and two-tailed Mann-Whitney test. Additional NSG 
mice underwent survival analyses with Kaplan–Meier curves and a log rank (Mantel–Cox) test.  
Results: At 2 weeks post-treatment, BLI and MRI scans revealed significant reduction in tumor size for 
CLIO-ICT plus radiation treated tumors compared to monotherapy or vehicle-treated tumors. 
Combining CLIO-ICT with radiation therapy significantly decreased microvessel density, decreased 
GICs, increased caspase-3 expression, and prolonged the survival of GBM-bearing mice. CLIO-ICT 
delivery to GBM could be monitored with MRI. and was not significantly different before and after 
radiation. There was no significant caspase-3 expression in normal brain at therapeutic doses of 
CLIO-ICT administered. 
Conclusion: Our data shows additive anti-tumor effects of CLIO-ICT nanoparticles in combination with 
radiotherapy. The combination therapy proposed here could potentially be a clinically translatable 
strategy for treating GBMs. 
Key words: glioblastoma, glioblastoma initiating cells, theranostic nanoparticle, radiation therapy, imaging, 
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Introduction 
Glioblastoma multiforme (GBM) is one of the 
deadliest neoplasms in children and young adults, 
with a median survival of 12-14 months [2, 3]. The 








and post-operative chemo/radiotherapy [4-6]. When 
exposed to ionizing radiation, GBM tumor cells 
undergo DNA damage and tumor cell death [7]. 
However, glioblastoma initiating cells (GICs) pose a 
challenge to achieving tumor response to radiation 
therapy. GICs are a subpopulation of quiescent cells 
that can activate DNA damage repair pathways, 
escape the toxic effect of radiation and subsequently 
induce tumor recurrence [8, 9]. Increasing doses of 
radiation have been used to target GICs but systemic 
toxicity is of significant concern [10]. Therefore, 
finding effective combinations of radiation with other 
therapeutic methods to target GICs is critical for the 
development of more effective anti-GBM strategies. 
The use of nanoparticles, in particular, is attractive 
given the advantages of improved plasma half-life, 
bio-availability, and sustained controlled drug release 
[11].  
We have recently developed and validated a 
treatment approach for GBM with theranostic 
nanoparticles (TNPs) in mouse models (Figure 1) [1]. 
Briefly, the TNPs are composed of FDA-approved 
cross-linked iron oxide nanoparticles (CLIO) and the 
highly effective vascular disrupting agent (VDA) 
azademethylcolchicine (ICT2552). CLIO and ICT2552 
are linked through an MMP-14-cleavable linker to 
afford the MMP-14 activatable theranostic drug, 
CLIO-ICT [12]. Matrix metalloproteinase 14 (MMP-14) 
is a membrane-bound protein playing an important 
role in the stemness of aggressive cancers, including 
GBM [13-15], which makes it an appealing therapeutic 
target for GICs. 
Here, we propose a new strategy of combining 
theranostic nanoparticles with radiation therapy (RT) 
for improved treatment of glioblastomas. The 
theranostic nanoparticles disrupt the blood brain 
barrier in the tumor tissue through MMP-14 mediated 
activation of the VDA prodrug. MMP-14 activation 
releases the vascular disrupting agent, ICT, which 
initiates a positive feedback loop of nanoparticle 
uptake and subsequent drug release. BBB breakdown 
releases the therapeutic drug ICT to the perivascular 
niche, where GICs are preferentially located. Since 
MMP-14 is abundant in GBM and not normal brain 
[13, 16-19], CLIO-ICT provides highly specific 
destruction of tumor vasculature and highly specific 
elimination of GBM tumor cells and GICs residing in 
the perivascular niche. Additionally, the CLIO 
nanocarrier allows for in vivo drug tracking with 
magnetic resonance imaging (MRI) [1][12].  
Thus, we hypothesize that CLIO-ICT, by 
targeting GICs, will have additive anti-GBM effects in 
combination with radiation. In addition, we postulate 
that CLIO-ICT will improve the efficacy of 
radiotherapy with marginal toxic effects to the normal 
brain and visceral organs. 
Methods 
Chemicals and antibodies. The following 
antibodies were used: MMP-14 (Santa Cruz), CD31 
(Abcam), Desmin (Abcam), CD15 (Abcam), and 
cleaved caspase-3 (Cell Signaling Technology). The 
following chemicals were used: Ferumoxytol (AMAG 
Pharmaceuticals). ICT and TNP were synthesized and 
characterized according to a previous protocol [1]. 
 
 
Figure 1: Illustration of additive effects of CLIO-ICT on radiotherapy. Radiotherapy targets glioblastoma cells but has a limited effect on glioblastoma initiating cells 
(GICs). GICs are often radioresistant and important for tumor recurrence. CLIO-ICT targets the vascular niche and indiscriminately induces apoptosis of both highly proliferated 
GBM cells and quiescent GICs. Therefore, CLIO-ICT could potentially overcome radioresistance and increase the efficacy of radiotherapy in GBMs. 




Cell culture. A patient-derived GBM cell line, 
GBM39, and a murine GBM cell line, CT-2A, were 
used in vitro and in vivo. The cell lines GBM39 and 
CT-2A were kindly provided by Dr. Sanjiv Sam 
Gambhir and Dr. Samuel Cheshier (Stanford 
University). CT-2A cells were grown in DMEM (Life 
Technologies) containing 10% FBS and 1% 
Penicillin/Streptomycin (Life Technologies). GBM39 
were cultured as floating cellular spheres as 
previously described [20]. All cell lines were 
authenticated and confirmed to be mycoplasma 
negative using the MycoAlert Mycoplasma Activity 
Kit (Lonza). All cell lines used were from early 
passages and were transfected with firefly luciferase 
enzyme to enable monitoring of tumor growth using 
bioluminescence imaging. 
Animal models. To generate orthotopic GBM 
xenografts, 300,000 tumor cells were injected 
stereotactically into the striatum of 8-week-old female 
NOD scid gamma (NSG) and C57BL/6J mice, using 
the following coordinates: 2 mm posterior to the 
bregma, 2 mm lateral to the midline, and 3 mm deep 
with respect to the surface of the skull. All animal 
maintenance, handling, surveillance, and 
experimentation were performed in accordance with 
and approval from the Stanford University 
Administrative Panel on Laboratory Animal Care 
(Protocol 24965). 
MMP-14 expression in patient tumor and 
murine tissues. To confirm that human GBMs have 
greater MMP-14 expression than normal brain to 
activate CLIO-ICT, we evaluated the expression of 
MMP-14 in GBM specimen from 5 
chemotherapy-naïve human patients (kindly 
provided by Dr. Jürgen Schlegel, Neuropathology, 
Technical University of Munich, Germany) as well as 
murine GBM specimen from GBM39-inoculated mice 
using immunohistochemistry (IHC). To estimate 
CLIO-ICT activation in normal organs, we 
additionally evaluated MMP-14 expression in murine 
lung, liver, heart, kidney, and bone marrow obtained 
from three C57BL/6J mice. IHC for MMP-14 was 
performed using the micro-polymer-IHC detection kit 
(Abcam) following the manufacturer’s instructions. 
Representative images were captured using a Zeiss 
AxioImager Widefield fluorescence microscope with a 
20X objective for whole-slide imaging (evaluated 
according to Immunoreactivity Score (IRS) system, 
using the following scores for percentage of positive 
cells: Negative (0), ≤ 10% (1), ≥ 11% and ≤ 50% (2) [21], 
≥ 51% and ≤ 80% (3) [22], ≥ 81% (4) [21, 22]. 
Dose response studies. Fifteen NSG mice and 
fifteen C57BL/6J mice were randomized in five 
groups (3 mice/group) receiving CLIO-ICT 
intravenously at different doses (0, 1, 2, 5 and 10 
mg/kg ICT; 0, 4.25, 8.5, 17, 34 mg/kg Fe). PBS was 
administered as vehicle in NSG and C57BL/6J mice 
without CLIO-ICT treatment. Bioluminescence 
imaging (BLI) was used to determine the anti-tumor 
effects of CLIO-ICT at various doses. The dose at 
which we observed maximum inhibition of tumor 
growth was considered as the optimum therapeutic 
dose in vivo. 
Monitoring tumor growth with BLI. Tumor 
formation of the animals were scored by BLI (twice 
per week after inoculation). Luminescent imaging 
was performed on an IVIS Spectrum (Caliper Life 
Science) and quantified using Living Image 4.0 
software. D-Luciferin (firefly) potassium salt solution 
(Biosynth) was prepared (15 mg/mL in PBS) and 
injected intraperitoneally (90 mg/kg, ~150 µL). Total 
flux (photons per second) values were obtained by 
imaging repeatedly until peak radiance was achieved 
and quantified with Living Image 4.0 software. BLI 
was repeated at the end of the treatment.  
Toxicity studies. Toxicity was evaluated by 
hematoxylin and eosin (H&E) staining, aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), and creatinine activities. An additional set of 
thirty non-tumor bearing C57BL/6J mice (6 
mice/group) received intravenous injections of PBS, 
CLIO-ICT (10 mg/kg ICT; 34 mg/kg Fe), CLIO-ICT 
(70 mg/kg ICT; 238 mg/kg Fe), colchicine (2 mg/kg), 
or colchicine (10 mg/kg). Given that our theranostic 
drug is activated in tissue by MMP-14 to release the 
vasculature disruptive agent, azademethylcolchicine 
(a colchicine derivative), we used equimolar doses of 
colchicine, assuming that all CLIO-ICT is cleaved in 
target tissues. Colchicine 2 mg/kg and 10 mg/kg 
corresponds to 10 mg/kg ICT and 70 mg/kg ICT, 
respectively. After day 5 of treatment, blood was 
collected into heparinized tubes to separate the 
plasma and stored in -80 °C. Liver toxicity was 
assayed using ALT/SGPT Activity Kit (BioVision 
K752-100) and AST/SGOT Activity Assay Kit 
(BioVision K753-100) following the manufacturer’s 
instructions. Renal toxicity was assayed using 
Creatinine (CRE) Assay Kit (MyBioSource 
MBS2540563) following the manufacturer’s 
instructions. Several organs (liver, heart, kidney, 
spleen, bone marrow, and brain) were harvested from 
all animals and fixed in 10% neutral buffered formalin 
for 24 h, followed by 70% ethanol at room 
temperature for 24 h. Organs were then embedded in 
paraffin for 3 h at 67°C. Coronal sections (5 μm thick) 
were stained with hematoxylin and eosin, and images 
were acquired with Eclipse E800 camera (Nikon, 
USA). [1].  
Efficacy of CLIO-ICT or/and radiation 
combination therapies. Twenty-eight NSG mice and 




twenty-four C57BL/6J mice with GBM were 
randomized into five different treatment groups (n = 6 
mice/group), which were treated as follows: Group 1: 
CLIO-ICT treatment (10 mg/kg ICT, 34 mg/kg Fe), 
Group 2: radiation therapy (10 Gy), Group 3: 
CLIO-ICT + radiation therapy (same doses as in 
groups 1 and 2), Group 4: phosphate buffered saline 
(PBS), and Group 5: temozolomide (TMZ, 33 mg/kg) 
+ radiation therapy. In group 5, two mice died of their 
brain cancer before completion of the experiment. 
Once tumor growth had been confirmed by BLI, the 
above-mentioned therapeutic regimen was 
administered on day 0 and day 7. Radiation therapy 
preceded intravenous injection of the therapeutic 
nanoparticles by 3 hours.  
Computed tomography (CT) and radiotherapy. 
Treatment planning and precise delivery of radiation 
was performed using a PXi X-Rad SmART cabinet 
irradiator (Precision X-Ray Inc., North Branford, CT). 
The system has the X-ray tube and the detector plate 
mounted on U shape gantry that rotates 360° in X and 
Y plane around the animal stage. The animal stage is 
supplied by a nose cone delivering isoflurane 
anesthesia and can move ±10 cm in the X, Y directions 
and ±15 cm in Z direction. CT images were acquired 
to facilitate treatment planning using a beam energy 
of 40 kVp, a beam filter of 2 mm Al and a voxel size of 
0.2 or 0.1 mm. Therapeutic irradiations were 
performed using an X-ray energy of 225 kVp and a 
current of 13 mA producing a dose rate of 300 
mGy/min at the isocenter. A single dose of 10 Gy was 
delivered using a 10 mm collimator. The treatment 
planning was performed with an open source RT 
image software package, version 3.13.1 running on 
IDL version 8.5.1, where the CT images were used as a 
reference to decide the beam angle and collimator size 
[21, 23, 24]. 
Magnetic resonance imaging (MRI). We 
evaluated tumor delivery of CLIO-ICT in 
GBM-bearing mice using MRI. GBM39-bearing mice 
underwent MRI before, 24 hours after, and 14 days 
after treatment with PBS, radiation, CLIO-ICT, 
radiation + CLIO-ICT, or radiation + TMZ. MRI 
studies of GBM-bearing mice were performed on a 7T 
MR scanner (Bruker Biospin, Billerica, MA), using an 
appropriate surface coil and the following pulse 
sequences with a field of view of 2 cm × 2 cm and a 
slice thickness of 0.5 mm: T2-weighted fast spin echo 
(FSE): repetition time (TR): 3476 ms, echo time (TE): 33 
ms, flip angle α: 90° and T2 multi-slice multi-echo 
(MSME): TR: 2964 ms, TE: 8, 16, 24, 32, 40, 48, 56, 64, 
72, 80, 88 and 96 ms, α: 90°. T2 relaxation times of the 
tumors were calculated as a quantitative measure of 
tumor contrast enhancement. 
Immunofluorescence. Mice in groups 1-5 were 
euthanized after the last imaging procedure for 
immunofluorescence. Brain tissues were also fixed in 
4% paraformaldehyde at 4°C overnight and later 
immersed in 30% sucrose for 2 days. Afterwards, 
brains were then embedded in OCT and stored in -80 
°C. Coronal sections (5 μm thick) were mounted on 
superfrost slides, rinsed with PBS and permeabilized 
with 0.1% Triton X-100 made in PBS solution for 15 
min. Subsequently, cells were blocked for 2 h and 
stained with primary antibodies overnight to 
determine GIC populations or to evaluate apoptosis 
upon treatment with radiation and/or CLIO-ICT. The 
following dilutions were used: CD31 (1:20, Abcam), 
desmin (1:50, Abcam), CD15 (1:200, Abcam) and 
cleaved caspase-3 (1:300, Cell Signaling Technology). 
Nuclei were counterstained with DAPI. Single 
endothelial cells or clusters of endothelial cells that 
were positive for CD-31 and desmin were considered 
as a vessel. Immunofluorescence images were 
acquired with a Leica SP8 confocal microscope (20X) 
using Leica AF software. Three “hot spots” from each 
slide were identified and photographed. The total 
number and positive number of cells were counted 
with Image-J in a blindfolded manner and were 
estimated as a mean ± SD in three different fields from 
three independent experiments. 
Survival studies. Mice with GBM39 tumors 
were treated with CLIO-ICT (10 mg/kg ICT, 34 
mg/kg Fe), radiation (10 Gy), CLIO-ICT + radiation, 
or PBS using the same protocols as above (6 
mice/group). Animal survival was evaluated from 
the first day of treatment until death. Body weight 
was measured twice a week. To avoid animal 
suffering, animals were euthanized when meeting 
predefined criteria, including loss of ability to 
ambulate, labored respiration, or inability to drink or 
feed. 
Prussian blue staining. The biodistribution of 
CLIO-ICT was investigated by Prussian blue staining. 
A set of nine mice with GBM39 tumors were treated 
with PBS, CLIO-ICT (10 mg/kg ICT, 34 mg/kg Fe), or 
CLIO-ICT (10 mg/kg ICT, 34 mg/kg Fe) + radiation 
(10 Gy) (3 mice/group). At 72 hours post-treatment, 
the mice were perfused with PBS and the tumor and 
visceral organs were harvested. The presence of iron 
in these specimens was investigated with Prussian 
blue staining using Iron Stain Kit (Sigma) according to 
the manufacturer’s instructions. Briefly, the tissue 
slides were deparaffinized and hydrated with 
deionized water. Subsequently, the slides were placed 
in working iron stain solution for 10 min. After 
rinsing with deionized water, the tissue was stained 
with Nuclear Fast Red solution (Sigma) for 5 min. 
Lastly, the tissue was rapidly dehydrated with alcohol 
and xylene and mounted for imaging. Images were 




acquired with Eclipse E800 camera (Nikon, USA). 
Three “hot spots” from each slide were identified and 
were photographed (20X). The blue dots were 
counted with Image-J in a blindfolded manner and 
were estimated as a total of blue dots per 10 cells ± SD 
in three different fields from three independent 
experiments. 
Intravital microscopy (IVM). A calvarial defect 
with a 5-mm diameter was created in an 8-week-old 
NOD scid gamma (NSG) mouse under anesthesia 
with 2% isoflurane delivered in 100% oxygen. To 
generate orthotopic GBM xenografts, GBM39 cells 
(Total = 300,000) were injected stereotactically into the 
striatum as described above. Prior to implantation, the 
cells were labeled with CellbriteTM Red (Biotium 
30023) according to the manufacturer’s instructions. 
The defect was covered with a cover glass slide and an 
MR-compatible cranial window chamber to enable 
real time imaging of tumor cells and tumor cell 
vasculature. For imaging, the head was immobilized 
using a stereotactic frame coupled with ear bars (Kopf 
Instruments, Tujunga, CA). Images were acquired 
before and after treatment with FITC-labeled 
CLIO-ICT or CLIO using a microscope (IV-100; 
Olympus, Tokyo, Japan) with Olympus UplanFL 
objectives and Olympus FluoView FV300 software. 
Time per pixel was set to 8–12.5 μsec, and voltage was 
set to 500–600 V. Images were analyzed with ImageJ 
software (National Institutes of Health; Bethesda, 
MD). 
Statistical analysis. The presence of statistical 
significance in the data set was determined using 
one-way ANOVA test. A nonparametric two-tailed 
Mann–Whitney test was used to compare two groups, 
unless otherwise specified. Results were presented as 
mean ± SD. Kaplan–Meier survival curves were 
compared using the log-rank (Mantel–Cox) test. The 
level of significance was set at p < 0.05, as compared 
with the control group. Statistical analyses were 
carried out with Prism 6.0 software (GraphPad).  
Results 
Development of theranostic nanoparticles. As 
previously described, we developed ICT, a 
peptide-conjugate of the VDA azademethylcolchicine 
(ICT2552), which is cleaved by MMP-14 to release and 
activate the therapeutic drug [12, 25]. To overcome 
potential limited tumor retention and systemic 
toxicity of this small molecular therapeutic drug, we 
attached the ICT prodrug to the cross-linked iron 
oxide nanoparticle compound, ferumoxytol [12]. 
CLIO-ICT nanoparticles have a diameter of 21±3 nm 
(Dynamic Light Scattering) and a zeta potential of 
21±7 meV (Laser Doppler Electrophoresis). The 
number of ICT molecules per iron oxide nanoparticle 
was determined to be on average 4.7, based on the 
attached fluorescein absorption in samples with 
known nanoparticle concentration [12].  
Exression of MMP-14 in tumor and normal 
organs. As a prerequisite for CLIO-ICT activation in 
GBMs, we first investigated whether human GBMs 
express MMP-14. IHC confirmed that MMP-14 
protein levels in tumor regions of all GBM patient 
specimens were significantly (p < 0.001) higher 
compared to normal brain regions (Figure 2A). We 
confirmed MMP-14 expression in murine GBMs 
(Figure 2B) and demonstrated CLIO-ICT dose- 
dependent inhibition of tumor growth in both 
xenograft and syngeneic GBM models. With a dose of 
ICT (10 mg/kg) and Fe (34 mg/kg), CLIO-ICT 
showed the maximum anti-GBM effect in both human 
(Figure 2C & 2E) and murine GBMs (Figure 2D & 2F) 
– thus, this optimal dose was used for subsequent 
combination therapies with radiation. To exclude 
toxicity in normal organs, we screened tissue 
specimen of the brain and visceral organs for MMP-14 
expression (Figure 3A). MMP-14 expression in the 
tumor was twice as high as lung and liver and 3-4 
times higher than in the kidney, heart, and spleen 
(Figure 3A & 3B).  
Toxicity studies. Liver toxicity markers (AST 
and ALT in plasma) were significantly lower for mice 
treated with CLIO-ICT compared with mice treated 
with free colchicine (Figure 3D & Figure 3E, p < 
0.0001). Creatinine levels in plasma demonstrated a 
similar pattern at the therapeutic dose of CLIO-ICT 
(ICT 10 mg/kg and Fe 34 mg/kg (Figure 3F, p < 0.01). 
However, excessive doses of CLIO-ICT caused 
significantly increased creatinine compared to 
colchicine treated mice (Figure 3D, p < 0.0001). H&E 
staining further demonstrated signs of necrosis in 
brain, heart, kidney, liver, spleen, and bone marrow in 
colchicine treated animals (2 mg/kg, Figure 3C). By 
comparison, organs from CLIO-ICT-treated animals 
showed no signs of necrosis (ICT 10 mg/kg and Fe 34 
mg/kg, Figure 3C).  
CLIO-ICT biodistribution. To evaluate 
CLIO-ICT biodistribution, mice were treated with 
PBS, CLIO-ICT, or radiation + CLIO-ICT and then 
perfused with PBS 72 hrs later. Tissues were 
harvested and stained with Prussian blue to examine 
the extent of iron uptake in the tumor, brain and 
visceral organs (Supplementary Figure 1). Compared 
to PBS treated controls, we found significantly higher 
iron content in CLIO-ICT treated tumors (p < 0.001). 
In each treatment group, GBMs demonstrated 
significantly higher iron uptake than the normal 
brain, regardless of whether the mice were treated 
with CLIO-ICT alone (p < 0.001) or in combination 
with radiation (p < 0.001). The degree of iron uptake 




in the tumor between the monotherapy and combined 
therapy groups was not significantly different 
(Supplementary Figure S1) demonstrating consistent 
delivery of the TNPs to the tumor. 
Compared to PBS treated controls, there was no 
significant iron uptake in the heart, lung, or kidney in 
mice treated with CLIO-ICT. However, we found 
significantly higher iron content in the liver of mice 
treated with CLIO-ICT compared to mice treated with 
PBS (Supplementary Figure S1). Mice have an 
intrinsically high iron content in the spleen as one of 
the spleen’s chief roles is to filter blood and recycle 
iron from aging blood cells. The red pulp of the spleen 
is also home to mononuclear phagocytes (i.e., 
macrophages, dendritic cells, and monocytes) which 
are known to consume iron oxide particles [26]. Our 
results showed that the iron content in the spleen of 
mice treated CLIO-ICT and PBS was not significantly 
different. The radiation therapy was collimated to the 
brain only, therefore, we neither expected nor 
observed a difference in the iron staining of visceral 
organs between the CLIO-ICT and CLIO-ICT plus 
radiation treatment groups.  
Preliminary intravital microscopy studies in 
NSG mice with orthotopic GBM3 xenografts 
showed that intravenously administered CLIO-ICT 
disrupted the BBB and accumulated in the 
extravascular space of the tumor tissue 
(Supplementary Figure S2, green fluorescence). Since 
MMP-14 is overexpressed on both tumor endothelial 
cells and tumor cells, CLIO-ICT is activated and 
released in the tumor vasculature, leading to efficient 
breakdown of the blood brain barrier (BBB). After 
intravenous injection of FITC-conjugated CLIO-ICT, 
the FITC signal in the tumor interstitium was 
significantly more intense compared to the FITC 
signal in the tumor interstitium after intravenous 
injection of CLIO only (without attached vascular 
disrupting agent). This suggests that CLIO-ICT tumor 
accumulation is markedly increased due to 
 
Figure 2: Dose response studies of CLIO-ICT in human and murine GBMs. (A) MMP-14 immunohistochemistry staining of human GBM and normal human brain 
specimen (scale bar, 100 µm). Immunohistochemistry results were evaluated by a semi-quantitative approach. The score for intensity is 0, 1+, 2+, 3+. The percentage of cells 
is scored : Negative (0), ≤ 10% (1), ≥ 11% and ≤50% (2) [21], ≥ 51% and ≤ 80% (3) [22], ≥ 81% (4). The formula for integrate score: the score for the intensity × the score for 
percentage of positive cells. (B) MMP-14 staining in murine CT-2A GBM tumors and normal murine brain specimen (scale bar, 40 µm). Immunohistochemistry results were 
evaluated by a semi-quantitative approach as mentioned above. (C-F) Dose-dependent effects of CLIO-ICT: Bioluminescent in vivo images of human GBM39 tumors in NSG 
mice (C) and murine CT-2A tumors in C57BL/6J mice (D). Ratio of bioluminescence radiance before and after therapy for human GBM39 tumors (E) and murine CT-2A tumors 
(F). Results are represented as the mean ± SD (n = 3 for NSG mice, n = 2 for C57BL/6J mice), * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 
 




VDA-mediated vascular disruption. These findings 
correlated with results of the MRI studies: At 24 h 
after intravenous injection of CLIO-ICT treatment, 
tumor T2 relaxation times were significantly shorter 
compared to CLIO treated controls (p < 0.05). In 
addition, histology studies at later time points 
demonstrated tumor vessel disruption and reduced 
vessel density (quantified as reduced CD31 vessel 
staining) in CLIO-ICT treated groups compared to 
CLIO treated groups. CLIO treatment only did not 
have any effect on tumor vessels, CD31 vessel staining 
of CLIO treated tumors was not significantly different 
compared to PBS treated controls (data not shown). 
Additive effects of CLIO-ICT with radiation 
therapy. Next, we assessed whether CLIO-ICT 
improves the efficacy of radiotherapy for anti-GBM 
treatment. Two weeks after initiation of treatment, 
BLI scans revealed significant reduction in tumor size 
for radiation plus CLIO-ICT-treated GBM39 tumors 
(Figure 4A & 4B, p < 0.001) and CT-2A tumors (Figure 
4C & 4D, p < 0.001) compared to monotherapy or 
vehicle-treated tumors. Additional mice were treated 
with the standard of care therapy (TMZ + radiation), 
which inhibited tumor growth compared to untreated 
controls. However, the tumor volume of mice treated 
with TMZ + radiation did not change significantly 
compared to baseline scans before start of therapy 
(Supplementary Figure S3). MR scans further 
demonstrated CLIO-ICT delivery into tumors by a 
negative (dark) signal enhancement on T2-weighted 
MR images (Figure 5A & 5B). T2 relaxation times of 
tumors treated with CLIO-ICT or radiation plus 
CLIO-ICT were two-fold lower compared to radiation 
and PBS treated tumors. The T2 relaxation times of 
GBMs after treatment with CLIO-ICT and CLIO-ICT 
plus radiation was not significantly different (see 
Figure 5B, p > 0.05), suggesting that CLIO-ICT 
delivery to tumors did not change significantly with 
added radiation. Likewise, T2 relaxation times of 
normal brain regions were not significantly different 
between mice treated with CLIO-ICT, radiation plus 
CLIO-ICT, or PBS suggesting that CLIO-ICT did not 
accumulate in normal brain before or after radiation 
therapy (Figure 5C). 
 
 
Figure 3: Safety profile of CLIO-ICT. (A) MMP-14 immunohistochemistry staining of different organs (heart, kidney, spleen, liver and lung) in C57BL/6J mice (20X 
magnification). (B) Immunohistochemistry results were evaluated by a semi-quantitative approach as previously described. (C) Representative H&E images show significant 
necrosis in different organs in colchicine (2 mg/kg) treated mice (n = 6) (10X magnification). Black arrows indicate necrosis. Organs from CLIO-ICT (10 mg/kg ICT) treated mice 
appear normal and healthy. The graphs show liver toxicity markers, including (D) AST activity, (E) ALT activity, and (F) creatinine concentration in mice treated with PBS, 10 
mg/kg or 70 mg/kg CLIO-ICT, and 2 mg/kg or 10 mg/kg colchicine. Results are represented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 





Figure 4: Efficacy studies of radiation with/or CLIO-ICT therapy in vivo. Bioluminescence images of (A) NSG mice with orthotopic luciferase-expressing GBM39 
tumors or (C) C57BL/6J mice with orthotopic GFP-luciferase-expressing CT-2A tumors. Mice were treated with CLIO-ICT (10 mg/kg ICT, 34 mg/kg Fe) and/or radiation (10 Gy). 
PBS treatment served as control. Corresponding total flux of tumors before and during treatment are shown for (B) NSG and (D) C57BL/6J mice. All mice were treated on 
Day 0 and again on Day 7. Results are represented as mean ± SD from six animals, * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. Pre = pre-therapy. 
 
Figure 5: MR scans after radiation with/or CLIO-ICT therapy. (A) Representative coronal T2-weighted MR images of the brain of NSG mice with GBM39 tumors 
before and after CLIO-ICT (10 mg/kg ICT, 34 mg/kg Fe) and/or radiation (10 Gy) treatment (24 hr and 14 d). PBS treatment served as control. Theranostic nanoparticle delivery 
is demonstrated by hypointense (negative/dark) tumor enhancement in CLIO-ICT and CLIO-ICT + radiation treated animals. Yellow arrows indicate the site of tumor growth. 
(B) Corresponding T2 relaxation times of tumors before and 24 hr after therapy. Note significant shortening of T2 relaxation times of tumors after administration of CLIO-ICT. 
(C) T2 relaxation times of the normal brain before and 24 hr after therapy. Data represent mean ± SD from six animals, * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 





Figure 6: Effect of mono- or combined-therapy on GBM vasculature and GIC population. (A) Representative confocal images depicting the effect of mono and 
combination therapy on tumor vasculature, GICs, and GBM cell death. GBM vasculature is outlined by staining with endothelial cell marker-CD31 and pericyte marker-desmin; 
GICs are identified using CD15, and GBM cell death is identified with cleaved caspase-3 (20X magnification). (B) Graphs show quantification of tumor microvessel density (MVD), 
CD15, and cleaved caspase-3 area. Results are represented as mean ± SD from six animals, * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. Tissue sections are from 
mice that were sacrificed 15 days post-treatment. Ctl = PBS control, R = radiation, C = CLIO-ICT, R+C = radiation + CLIO-ICT. 
 
 
Figure 7: Radiation and CLIO-ICT combination therapy significantly 
improves survival of GBM39 tumor-bearing mice. Kaplan-Meier survival 
curves demonstrate a significant survival benefit in CLIO-ICT and radiotherapy 
co-treated group compared with monotherapy or vehicle control (n = 6), log-rank 
Mantel-Cox test, * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 
 
Vasculature staining with CD31 and desmin 
showed reduced vascular density for mice treated 
with combination therapy (Figure 6A & 6B). The 
staining for CD15, a known marker for glioblastoma 
initiating cells [62], also decreased substantially upon 
the combination treatment compared to monotherapy 
and control groups (Figure 6A & 6B). Furthermore, 
the amount of active caspase-3 increased significantly 
in radiation and CLIO-ICT co-treated groups 
compared to the PBS treated control group (p < 0.001), 
suggesting that apoptosis was induced by the former 
treatment (Figure 6A & 6B). As expected, we also 
found that the combination therapy significantly 
prolonged the survival of GBM–bearing mice 
compared to control or monotherapy treated animals 
(Figure 7, p < 0.001). We used H&E staining to 
confirm that the entire tissue section stained was 
tumor, which could be recognized by extensive 
hyperplasia (Supplementary Figure S4). 
Discussion 
Despite advances in therapy, the prognosis for 
GBM patients is still devastating. The recurrence rate 
of malignant gliomas is approximately 90% [27]. 
Despite aggressive treatment with surgical resection 
and subsequent chemo/radiation therapy, resistance 
to adjuvant therapy enhances cancer cell survival, 
which is a critical cause for tumor relapse [4, 5, 28]. 
While effective for eradicating GBM cancer cells, 
radiotherapy is less effective for GICs [8, 29]. 
Radiation therapy kills cancer cells by inducing 
irreparable DNA double-strand breaks, thus highly 




proliferating cancer cells are more radiosensitive than 
quiescent GICs. Combining radiation therapy with 
other cancer therapies has shown benefits over 
monotherapies, including targeting multiple 
biochemical pathways, genes, or cell cycle 
checkpoints to overcome resistance in heterogeneous 
tumors [30, 31]. However, thus far, a curative 
combination therapy for GBM that can target GICs 
without added toxic effects has not been found. 
Here we investigated a new combined 
therapeutic approach against GBMs using radiation 
and the MMP-14-activatable theranostic nanoparticle, 
CLIO-ICT. We found that the combination therapy 
demonstrated significant tumor response and 
prolonged survival time compared to monotherapy or 
no treatment. The data suggests that CLIO-ICT can 
improve the therapeutic efficacy of radiation therapy 
for GBM treatment. There are several examples in the 
literature where combination therapies involving 
nanoparticles have enhanced therapeutic outcomes 
without added toxicity, enhanced efficacy, and 
overcome drug resistance to elicit sustained treatment 
responses in cancer patients [31-33]. Given our 
promising results and the fact that CLIO-ICT is based 
on an FDA-approved iron oxide scaffold, this could 
potentially be a translatable treatment option for 
human GBMs.  
The combination of CLIO-ICT with ionizing 
radiation is particularly potent because CLIO-ICT is 
activated through an MMP-14-cleavable linker and 
thereby, only activated in the tumor tissue. This limits 
off-target toxicities to the normal brain. MMP-14 is a 
membrane-bound protein that plays a role in the 
degradation of structural proteins in the extracellular 
matrix and has been identified as an important target 
for cancer diagnostics and therapy [13, 34]. In 
addition, MMP-14 is also regarded as a marker for 
GICs [13-15], which makes it a target for our drug. As 
expected, we found a significant reduction in CD15 
staining (a marker for glioblastoma initiating cells) in 
CLIO-ICT and CLIO-ICT plus radiation treated mice, 
confirming that CLIO-ICT targets cells that have been 
previously reported as radio-resistant.  
One concern with combination therapies is 
toxicity [35]. ICT is a derivative of colchicine, which is 
a VDA. VDAs are used currently in clinical practice, 
but they are highly toxic. For example, significant 
cardiotoxicity has been observed in patients treated 
with the VDAs DMXAA [36] and combretastatin A4 
[37, 38]. Colchicine is an effective VDA not only 
because it binds to tubulin and shuts down mitosis 
but also because it activates platelets which causes 
serotonin release. Serotonin is also a VDA, acting 
through G-protein-coupled receptors to generate actin 
stress fibers and decrease blood flow [39]. Our data 
shows that CLIO-ICT does not accumulate in the 
heart, because the ICT is covalently linked to 
nanoparticles which do not extravasate under normal 
physiological conditions. Our data are in accordance 
with our previous observations which showed no 
significant cardiotoxicity after CLIO-ICT treatment 
[37]. While we showed that our CLIO-ICT can 
potentiate the effect of radiation therapy, radiation 
therapy can also potentiate the efficacy of our drug. 
Previous investigators described that radiation can 
cause an upregulation of MMPs [40, 41]. Greater 
expression of MMPs would result in enhanced 
CLIO-ICT activation in the tumor tissue.  
VDAs have other advantages to overcome tumor 
resistance to radiotherapy. It is reported that larger 
tumors are less radiosensitive than small tumors, 
which might be due to increased hypoxic regions. 
VDAs cause a rapid shutdown of perfusion in the 
established tumor vasculature, leading to tumor cell 
ischemia and secondary tumor cell death [42-44]. 
These agents have the potential to destroy existing 
tumor masses and may, therefore, be particularly 
suitable for treating large tumors. [45] 
Complementarily, conventional cytotoxic 
radiotherapy has been shown to eradicate a viable rim 
of tumor cells at the tumor periphery after VDA 
treatment [46]. This observation might be explained 
by the fact that VDAs are able to kill cancer cells also 
in hypoxic regions which are less radiosensitive. The 
remaining rim of viable cells after mono-VDA 
treatment is believed to be well-oxygenated and thus 
present an excellent target for radiotherapy. To 
achieve the strongest additive effect, we treated our 
animals first with radiotherapy and next with 
CLIO-ICT (at 3 hours post-radiotherapy), since it has 
been suggested that blood flow needs to be 
established to obtain maximum radiosensitization of 
the tumor [47].  
Conclusion 
In summary, intravenous treatment with 
theranostic CLIO-ICT nanoparticles enhanced the 
efficacy of ionizing radiation for the treatment of GBM 
in mouse models in an additive manner, with limited 
toxicity to the normal brain or visceral organs. In 
addition, the use of superparamagnetic iron oxide 
nanoparticles as the backbone of our theranostic drug 
enabled in vivo drug tracking with MRI. Given the 
urgent need for new therapies and the shortcomings 
of current clinical approaches, this new combination 
therapy provides a new option for GBM treatment. 
Further studies to enable clinical translation of 
CLIO-ICT are under way. 





GBM: Glioblastoma multiforme; GIC: 
glioblastoma initiating cell; CLIO: cross-linked iron 
oxide nanoparticle; MMP: matrix-metalloproteinase; 
VDA: vasculature disrupting agent; MVD: 
microvessel density; EPR: enhanced permeability and 
retention[18]; MRI: magnetic resonance imaging; BLI: 
bioluminescence imaging; CT: computed 
tomography; ICT2588: azademethylcolchicine- 
peptide conjugate; ICT: modified analogue of 
ICT2588; DMXAA: 5,6-dimethylxanthenone-4-acetic 
acid. 
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